114.30
price up icon0.22%   0.25
pre-market  プレマーケット:  114.54   0.24   +0.21%
loading
前日終値:
$114.05
開ける:
$114.19
24時間の取引高:
1.31M
Relative Volume:
0.63
時価総額:
$6.61B
収益:
$76.81M
当期純損益:
$-162.42M
株価収益率:
-38.23
EPS:
-2.99
ネットキャッシュフロー:
$-122.49M
1週間 パフォーマンス:
+0.47%
1か月 パフォーマンス:
+64.74%
6か月 パフォーマンス:
+58.40%
1年 パフォーマンス:
+74.16%
1日の値動き範囲:
Value
$114.07
$114.65
1週間の範囲:
Value
$113.68
$114.65
52週間の値動き範囲:
Value
$47.86
$114.65

Arcellx Inc Stock (ACLX) Company Profile

Name
名前
Arcellx Inc
Name
セクター
Healthcare (1106)
Name
電話
240-327-0603
Name
住所
800 BRIDGE PARKWAY, REDWOOD CITY
Name
職員
163
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
ACLX's Discussions on Twitter

Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ACLX
Arcellx Inc
114.30 6.59B 76.81M -162.42M -122.49M -2.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Arcellx Inc Stock (ACLX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-12 ダウングレード Rothschild & Co Redburn Buy → Neutral
2026-01-07 再開されました UBS Buy
2025-12-22 開始されました Wells Fargo Overweight
2025-11-18 開始されました Wolfe Research Peer Perform
2025-10-16 開始されました Stifel Buy
2025-06-17 開始されました Citigroup Buy
2024-10-08 開始されました Redburn Atlantic Buy
2024-09-03 開始されました Cantor Fitzgerald Overweight
2024-05-31 開始されました Piper Sandler Overweight
2024-03-07 開始されました Morgan Stanley Overweight
2024-01-04 繰り返されました Needham Buy
2023-12-19 開始されました Scotiabank Sector Outperform
2023-10-30 開始されました TD Cowen Outperform
2023-10-17 開始されました UBS Buy
2023-05-18 開始されました Truist Buy
2023-04-14 開始されました Robert W. Baird Outperform
2023-03-14 開始されました Stifel Buy
2023-02-13 開始されました H.C. Wainwright Buy
2022-12-13 再開されました BofA Securities Buy
2022-10-31 開始されました Guggenheim Buy
2022-10-27 開始されました Needham Buy
2022-07-20 開始されました Canaccord Genuity Buy
2022-03-01 開始されました BofA Securities Buy
2022-03-01 開始されました SVB Leerink Outperform
すべてを表示

Arcellx Inc (ACLX) 最新ニュース

pulisher
06:12 AM

Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union

06:12 AM
pulisher
01:29 AM

Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat

01:29 AM
pulisher
Mar 04, 2026

Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire

Mar 04, 2026
pulisher
Mar 04, 2026

Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Mar 04, 2026
pulisher
Mar 04, 2026

Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga

Mar 04, 2026
pulisher
Mar 04, 2026

Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com

Mar 04, 2026
pulisher
Mar 03, 2026

Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com Australia

Mar 03, 2026
pulisher
Mar 03, 2026

Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times

Mar 03, 2026
pulisher
Mar 03, 2026

Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com

Mar 03, 2026
pulisher
Mar 03, 2026

Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com

Mar 03, 2026
pulisher
Mar 03, 2026

Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 03, 2026

Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka

Mar 03, 2026
pulisher
Mar 03, 2026

ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance

Mar 03, 2026
pulisher
Mar 02, 2026

Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement - The Globe and Mail

Mar 02, 2026
pulisher
Mar 02, 2026

Arcellx President Sells $10M Worth of Shares After Acquisition Announcement - The Globe and Mail

Mar 02, 2026
pulisher
Mar 02, 2026

TD Cowen Downgrades Arcellx to Hold From Buy - marketscreener.com

Mar 02, 2026
pulisher
Mar 02, 2026

Arcellx stock rating cut to Hold by TD Cowen on Gilead deal - Investing.com UK

Mar 02, 2026
pulisher
Mar 02, 2026

Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX - MarketBeat

Mar 01, 2026
pulisher
Feb 28, 2026

Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 89,916 Shares of Stock - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Arcellx CEO Elghandour sells $10.2 million in ACLX stock - Investing.com

Feb 27, 2026
pulisher
Feb 27, 2026

Tax-withholding sale by Arcellx (NASDAQ: ACLX) director Elghandour - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

Arcellx, Inc. Hits Day High with 77.43% Surge in Stock Price - Markets Mojo

Feb 27, 2026
pulisher
Feb 27, 2026

E-Trade Financial (NASDAQ: ACLX) files Form 144 listing 164,548 RSU shares - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

Taxation With Representation: Linklaters, Wilson Sonsini - Law360

Feb 27, 2026
pulisher
Feb 27, 2026

Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey

Feb 27, 2026
pulisher
Feb 27, 2026

Arcellx, Inc. Experiences Evaluation Revision Amid Strong Market Performance and Volatility - Markets Mojo

Feb 27, 2026
pulisher
Feb 27, 2026

Arcellx (ACLX) Posts US$228.9m TTM Loss Testing Bullish Profitability Narratives - Sahm

Feb 27, 2026
pulisher
Feb 26, 2026

Arcellx (NASDAQ:ACLX) Announces Earnings Results, Meets Estimates - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Arcellx, Inc. SEC 10-K Report - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

ACLX SEC FilingsARCELLX INC 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Guggenheim Downgrades Arcellx to Neutral From Buy, Adjusts PT to $115 From $120 - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

Arcellx, Inc. Opens with a 77.48% Gain, Outperforming S&P 500's 0.69% Increase - Markets Mojo

Feb 26, 2026
pulisher
Feb 26, 2026

Gilead’s Arcellx Deal And HIV Data Reframe Growth And Valuation Story - Sahm

Feb 26, 2026
pulisher
Feb 26, 2026

Guggenheim downgrades Arcellx stock rating on Gilead acquisition By Investing.com - Investing.com Nigeria

Feb 26, 2026
pulisher
Feb 26, 2026

Guggenheim downgrades Arcellx stock rating on Gilead acquisition - Investing.com India

Feb 26, 2026
pulisher
Feb 25, 2026

Arcellx, Inc. Hits New 52-Week High of $114.26, Up 110% Yearly - Markets Mojo

Feb 25, 2026
pulisher
Feb 25, 2026

Insider sells 19,675 shares — E-TRADE Financial (ACLX) files Form 144 - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

Arcellx (ACLX) CFO reports tax-driven share sale after exercising 20,530 units - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

Arcellx CFO Michelle Gilson Sells Shares to Cover Tax Obligations - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge? - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Arcellx set to report earnings amid pending Gilead acquisition By Investing.com - Investing.com South Africa

Feb 25, 2026
pulisher
Feb 25, 2026

Arcellx set to report earnings amid pending Gilead acquisition - Investing.com

Feb 25, 2026
pulisher
Feb 25, 2026

Gilead Snaps Up Arcellx For $115 Per ShareA $7.8 Billion Bet On Cancer Therapy - Bitget

Feb 25, 2026
pulisher
Feb 25, 2026

Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga

Feb 25, 2026
pulisher
Feb 25, 2026

Arcellx (NASDAQ:ACLX) Downgraded to Hold Rating by Evercore - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Arcellx (NASDAQ:ACLX) Lowered to Hold Rating by Leerink Partners - MarketBeat

Feb 25, 2026

Arcellx Inc (ACLX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
大文字化:     |  ボリューム (24 時間):